bms-275183

Small moleculeexperimental

Clinical trial activity

6 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Oct 1, 2004 (NCT00207025)

Timeline

2000s

Jan 1, 2004
Earliest Phase 1 Sponsor(trial)
Jan 1, 2004
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C

Mol. weight: 845.94 g/mol
Lipinski Ro5: 2 violation(s)
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

ChEMBLCHEMBL4297268 ↗

Also known as

bms-275183
bms-275183
bms-275183

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT00332748	Phase 1	Dec 1, 2006	Bristol-Myers Squibb
NCT00359450	Phase 2	Jul 1, 2006	Bristol-Myers Squibb
NCT00326131	Phase 1	Apr 1, 2006	Bristol-Myers Squibb
NCT00103831	Phase 1/Phase 2 (Phase 2)	Feb 15, 2005	Bristol-Myers Squibb
NCT00099879	Phase 2	Dec 21, 2004	Bristol-Myers Squibb
NCT00207025	Phase 1	Oct 1, 2004	Bristol-Myers Squibb

Showing 6 of 6 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Bristol-Myers Squibb	For profit	6	6	2	2004

1 organizations

Page 1 / 1